grant. Subtitle E—Environmental Justice and Environmental Justice Advocates Sec. 20601. Findings. Sec. 20602. Sense of Congress. Subtitle F—Endometrial Cancer Research and Education Sec. 20701. Short title. Sec. 20702. Findings. Sec. 20703. Expanding research and education with respect to endometrial cancer. Subtitle G—Donald Payne Sr. Colorectal Cancer Detection Sec. 20801. Short title. Sec. 20802. Medicare coverage for FDA-approved qualifying colorectal cancer screening blood-based tests. Subtitle H—Environmental Justice Act Sec. 20901. Short title. Sec. 20902. Purposes. Sec. 20903. Definitions. Sec. 20904. Interagency Federal Working Group on Environmental Justice. Sec. 20905. Federal agency actions to address environmental justice. Sec. 20906. National Environmental Justice Advisory Council. Sec. 20907. Environmental justice grant programs. Sec. 20908. Consideration of cumulative impacts and persistent violations in certain permitting decisions. Sec. 20909. Implied rights of action and common law claims. Sec. 20910. Private rights of action for discriminatory practices. Sec. 20911. Severability. Subtitle I—Strengthening Health Care and Lowering Prescription Drug Costs Sec. 21001. Short title. Part 1—Lowering Prescription Drug Costs Subpart A—Bringing low-Cost options and competition while keeping incentives for new generics Sec. 21011. Change conditions of first generic exclusivity to spur access and competition. Subpart B—Protecting consumer access to generic drugs Sec. 21015. Unlawful agreements. Sec. 21016. Notice and certification of agreements. Sec. 21017. Forfeiture of 180-day exclusivity period. Sec. 21018. Commission litigation authority. Sec. 21019. Statute of limitations. Subpart C—Creating and restoring equal access to equivalent samples Sec. 21021. Actions for delays of generic drugs and biosimilar biological products. Sec. 21022. REMS approval process for subsequent filers. Sec. 21023. Rule of construction. Subpart D—Study on role of Federal assistance in drug development Sec. 21025. Study on